Skip to main content
PLIANT THERAPEUTICS, INC. logo

PLIANT THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PLRX ISIN · US7291391057 LEI · 5493002Q5LITR7VHZH02 US Professional, scientific and technical activities
Open in API
Filings indexed 403 across all filing types
Latest filing 2022-02-03 Director's Dealing
Country US United States of America
Listing US PLRX

About PLIANT THERAPEUTICS, INC.

https://pliantrx.com/

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis and related diseases. The company leverages its expertise in integrin biology to create tissue-specific treatments. Its therapeutic approach centers on modulating integrin activity and inhibiting TGF-β1 signaling, which are key molecular drivers of fibrosis. Pliant utilizes its proprietary discovery platform to advance a pipeline of integrin-based product candidates, aiming to provide safer and more effective therapies for patients.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-02-03 English
FORM 4
Director's Dealing
2022-02-03 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 10, 2022, by Pliant Therapeutics, Inc. It announces the company's intention to conduct meetings at the 40th Annual J.P. Morgan Healthcare Conference and includes a corporate slide presentation as an exhibit. The text explicitly states that the information is being furnished, not filed, and is related to a presentation. The key phrase is 'the Company intends to utilize the corporate slide presentation furnished with this report as Exhibit 99.1.' This indicates the document is primarily about an investor presentation. The length is 3799 characters, which is relatively short but contains the presentation itself as an exhibit, not just an announcement of a report. Therefore, the best classification is Investor Presentation (IP).
2022-01-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results for the third quarter ended September 30, 2021, and that the press release is furnished as an exhibit. The document itself does not contain the financial results but references the press release. The length is 3724 characters, which is relatively short and consistent with a report announcing an event rather than containing full financial data. According to the rules, if a document is short and announces or furnishes a press release with financial results, it should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER). The document is not the earnings release itself but a filing to announce it. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-11-09 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes an announcement of positive interim clinical trial results and references an attached press release as Exhibit 99.1. The document length is 3805 characters, which is relatively short and primarily serves to announce an event rather than provide detailed financial data or comprehensive reporting. There are no full financial statements or detailed analysis present, and the document is not an earnings release or annual/interim report. It is also not a certification or officer attestation. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-09-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.